The company posted a 10.7% year-on-year drop in consolidated net profit at ₹420.8 crore for Q4 FY25, compared to ₹471.2 crore a year ago. However, revenue surged 27.1% to ₹3,079.4 crore, led by steady growth in chronic therapies, strong traction in consumer healthcare, and consolidation of the acquired BSV business.
EBITDA rose 16.5% to ₹683.2 crore, though the EBITDA margin narrowed to 22.2% from 24.2% last year, reflecting integration costs and regulatory challenges in the acute segment.
BSV, short for Bharat Serums and Vaccines, was acquired by Mankind to bolster its specialty portfolio in gynaecology and super specialty therapies. The company said BSV integration is progressing well, with a focus on improving R&D and scaling key brands.
For FY25, Mankind posted a revenue of ₹12,207 crore, up 19% YoY, with domestic sales contributing ₹10,675 crore and exports growing sharply by 88% to ₹1,532 crore. Adjusted EBITDA margins for the full year stood at 25.9%.
Vice Chairman and Managing Director Rajeev Juneja noted, “Q4 marks continued outperformance in chronic therapies, strong momentum in the consumer business, and successful BSV integration. This has been a transformative year, and we are laying the foundation for long-term sustainable growth.”
Mankind continues to lead the Indian pharmaceutical market by prescription count for the eighth consecutive year. Its consumer healthcare brands also posted double-digit growth, led by Manforce, Gas-O-Fast and HealthOK.
Shares of Mankind Pharma ended at ₹2,533.05, down 0.69% on the BSE.
